Connection
Robert Freedman to Cross-Over Studies
This is a "connection" page, showing publications Robert Freedman has written about Cross-Over Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.282 |
|
|
|
-
Olincy A, Blakeley-Smith A, Johnson L, Kem WR, Freedman R. Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder. J Autism Dev Disord. 2016 Dec; 46(12):3812-3817.
Score: 0.102
-
Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du YP, Soti F, Kem WR, Freedman R. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology. 2010 Mar; 35(4):938-42.
Score: 0.063
-
Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006 Jun; 63(6):630-8.
Score: 0.049
-
Adler LE, Olincy A, Cawthra E, Hoffer M, Nagamoto HT, Amass L, Freedman R. Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism. Neuropsychopharmacology. 2001 Jun; 24(6):671-9.
Score: 0.035
-
Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, Sobeih T, Wall MM, Choo TH, Vail B, Grinband J, Lieberman JA. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology. 2020 07; 45(8):1339-1345.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|